Histone antibodies are the reagents where specificity claims are most often wrong, and the reason is structural rather than commercial. The proteins are small, highly conserved and covered in modifications that sit within a few residues of each other, so an antibody raised against one mark routinely recognises a neighbouring one, the same mark on a different residue, or the unmodified tail. None of that shows up in a western blot of whole cell lysate, which is the image most datasheets lead with, so the questions worth asking are about the negative controls rather than the positive one.
A histone antibody igg fraction is not the same as a purified clone
Much of what is sold for this target is a polyclonal immunoglobulin fraction rather than a monoclonal, and the practical difference is lot to lot variation: each animal's response is its own, and an antibody that worked last year may not be the same reagent under the same catalogue number. Where a result will be built on, buy a monoclonal or a recombinant version if one exists, and if it does not, buy enough of one lot to finish the work and record the lot in the method. A polyclonal fraction also carries antibodies to everything else the animal met, which is why a blocking step with the unmodified peptide is worth doing once.
Which histone h3 antibody the question decides
The tail of this protein carries most of the marks people care about, and antibodies against it fall into three groups: those that recognise the protein whatever its state, those that recognise one modification at one residue, and those that claim a combination. The first group is the loading control; the second is the experiment; the third is the one to be sceptical about, because a claim about two marks on one tail needs evidence that the antibody fails when either is absent. Whichever group it is in, the useful part of the datasheet is the peptide array or the dot blot against the neighbouring marks.
Where histone 3 antibody naming goes wrong
The same target is written several ways across catalogues, spelled out, numbered, with and without the residue and the modification, and two of those forms can name antibodies with quite different behaviour. Buy on the immunogen sequence rather than the product name: the datasheet should state which peptide the antibody was raised against and which residue is modified, and where it does not, the name is not enough to know what you are getting. Recording the immunogen rather than the catalogue name is also what makes the method reproducible when the supplier renumbers its range.
What an acetylated lysine antibody can and cannot see
A pan modification antibody recognises the chemical group in many sequence contexts, which is useful for asking whether a treatment changed the amount of that mark overall and useless for asking where. Its signal is a sum across every protein in the sample that carries the group, so a change can come from anywhere, and the same antibody will differ in how well it sees the mark depending on the residues around it. Use it as a screen and follow it with a site specific antibody or with mass spectrometry, which is the only method that reads the position without an antibody's opinion.
The controls that make any of this believable
Three, and they are cheap next to the experiment. A peptide competition, where the unmodified and modified peptides are used to block the antibody and only the matching one abolishes the signal. A sample where the mark is expected to be absent or reduced, by inhibitor, by knockout of the writing enzyme or by a mutant residue. And a second antibody from a different clone or a different supplier, because two reagents agreeing is a much stronger statement than one reagent repeated. A figure without at least one of these is a statement about the antibody, not about the biology.
Questions people ask about histone antibody
Why does the same antibody give a different result in chromatin work and on a blot?
Because the epitope is presented differently: on a blot the protein is denatured and linear, in chromatin it is folded, bound to DNA and surrounded by other proteins, and an antibody that reads one may not read the other. Validate the reagent in the application it will be used in, and treat a datasheet image from a different application as unrelated evidence.
Is a recombinant antibody worth the extra cost here?
Usually, because the reagent stops being animal dependent: the same sequence is expressed every time, so the lot to lot variation that makes this target painful largely goes away. Where a long study or a published method depends on the reagent, that consistency is worth more than the saving on a polyclonal.
How do I know a modification specific antibody is really specific?
From a peptide array or dot blot in the datasheet covering the neighbouring marks and the unmodified peptide, and from your own competition experiment. Anything less is a claim rather than evidence, and on this family of targets the claim is wrong often enough to matter.
Is an anti-histone h3 antibody the same as a modification specific one?
No, and the naming hides it. A reagent named for the protein alone recognises it whatever its state and is a loading control; a modification specific reagent is named for the residue and the mark and is the experiment. Read the immunogen on the datasheet rather than the product name, because both are sold under labels that look alike.